FDA Brief

Warning letters Drugs

FDA warning letter to

ybycmeds

MediumIssued Sep 9, 2025Posted Sep 16, 2025Center for Drug Evaluation and Research (CDER)

FDA warns ybycmeds over website claims that compounded semaglutide and tirzepatide are similar to approved brand-name drugs.

What happened

FDA reviewed website content at https://ybycmeds.com in August 2025 and observed that the site offers compounded drug products including semaglutide and tirzepatide. FDA found claims that these products are similar to Ozempic, Wegovy, Mounjaro, and Zepbound. FDA says the claims are false or misleading because compounded drug products are not FDA-approved.

What FDA found

  1. FDA says the website claim that compounded semaglutide is similar to Ozempic or Wegovy is false or misleading because compounded drugs are not FDA-approved.

    FDCA § 502(a) and § 502(bb), 21 U.S.C. §§ 352(a), 352(bb)
  2. FDA says the website claim that compounded tirzepatide is similar to Mounjaro or Zepbound is false or misleading because compounded drugs are not FDA-approved.

    FDCA § 502(a) and § 502(bb), 21 U.S.C. §§ 352(a), 352(bb)
  3. FDA says the claims imply the products are the same as FDA-approved products when they are not.

    FDCA § 502(a) and § 502(bb), 21 U.S.C. §§ 352(a), 352(bb)
  4. FDA says introducing these drugs into interstate commerce is prohibited because their advertising is false or misleading.

    FDCA § 301(a), 21 U.S.C. § 331(a)
  5. FDA says receiving or delivering these misbranded drugs in interstate commerce is also prohibited.

    FDCA § 301(c), 21 U.S.C. § 331(c)

What FDA wants

FDA tells ybycmeds to take immediate action, including ceasing and desisting from using the misleading language, and to respond in writing within 15 working days describing steps taken to address the violations and prevent recurrence.

Who should pay attention

  • online sellers and telehealth sites offering compounded semaglutide or tirzepatide
  • compounding pharmacies that compare their products to brand-name drugs
  • weight-loss clinics and brands marketing compounded drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  2. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  3. Empower Clinic Services, LLC dba Empower Pharmacy

    FDA warned Empower Pharmacy over unapproved compounded semaglutide/tirzepatide copies and sterile manufacturing deficiencies that put patients at risk.

    High risk
  4. Buy Keta Online / www.buyketaonline.com

    FDA warns Buy Keta Online that its website sells unapproved and misbranded ketamine drugs to U.S. consumers.

    High risk